Pinnacle Associates Ltd. grew its place in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.3% within the third quarter, Holdings Channel.com experiences. The fund owned 1,307,304 shares of the corporate’s inventory after buying a further 29,597 shares throughout the quarter. Johnson & Johnson includes about 3.2% of Pinnacle Associates Ltd.’s holdings, making the inventory its third largest place. Pinnacle Associates Ltd.’s holdings in Johnson & Johnson have been value $204,907,000 as of its most up-to-date SEC submitting.
A number of different giant traders have additionally modified their holdings of JNJ. Worldwide Belongings Funding Administration LLC boosted its holdings in shares of Johnson & Johnson by 20,130.0% within the third quarter. Worldwide Belongings Funding Administration LLC now owns 3,454,473 shares of the corporate’s inventory valued at $559,832,000 after buying a further 3,437,397 shares throughout the interval. Marshall Wace LLP boosted its holdings in shares of Johnson & Johnson by 506.9% within the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the corporate’s inventory valued at $567,826,000 after buying a further 3,244,862 shares throughout the interval. Value T Rowe Associates Inc. MD boosted its holdings in shares of Johnson & Johnson by 16.8% within the first quarter. Value T Rowe Associates Inc. MD now owns 21,834,359 shares of the corporate’s inventory valued at $3,453,978,000 after buying a further 3,139,499 shares throughout the interval. Ninety One UK Ltd raised its stake in shares of Johnson & Johnson by 59.0% throughout the second quarter. Ninety One UK Ltd now owns 6,708,943 shares of the corporate’s inventory value $980,579,000 after buying a further 2,489,925 shares over the last quarter. Lastly, Swedbank AB bought a brand new stake in shares of Johnson & Johnson throughout the first quarter value roughly $331,178,000. 69.55% of the inventory is owned by institutional traders and hedge funds.
Analyst Rankings Adjustments
A number of equities analysis analysts have just lately commented on the corporate. StockNews.com upgraded Johnson & Johnson from a “purchase” score to a “strong-buy” score in a analysis observe on Saturday, September 14th. Wells Fargo & Firm upped their worth goal on Johnson & Johnson from $163.00 to $166.00 and gave the inventory an “equal weight” score in a analysis observe on Wednesday, October sixteenth. Morgan Stanley upped their worth goal on Johnson & Johnson from $169.00 to $175.00 and gave the inventory an “equal weight” score in a analysis observe on Wednesday, October sixteenth. The Goldman Sachs Group lower their worth goal on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” score for the corporate in a analysis report on Friday, July nineteenth. Lastly, TD Securities lower their worth goal on Johnson & Johnson from $195.00 to $185.00 in a analysis report on Thursday, July 18th. Six analysis analysts have rated the inventory with a maintain score, seven have assigned a purchase score and one has issued a robust purchase score to the corporate’s inventory. In accordance with MarketBeat.com, Johnson & Johnson at present has a consensus score of “Average Purchase” and a mean goal worth of $175.93.
Get Our Newest Inventory Evaluation on JNJ
Johnson & Johnson Buying and selling Down 0.5 %
Shares of JNJ inventory opened at $159.86 on Friday. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week excessive of $168.85. The inventory has a market cap of $384.88 billion, a P/E ratio of 23.13, a P/E/G ratio of two.90 and a beta of 0.52. The enterprise has a fifty day easy transferring common of $163.39 and a 200-day easy transferring common of $155.35. The corporate has a fast ratio of 0.85, a present ratio of 1.07 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final posted its quarterly earnings knowledge on Tuesday, October fifteenth. The corporate reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The enterprise had income of $22.47 billion for the quarter, in comparison with analyst estimates of $22.17 billion. Johnson & Johnson had a return on fairness of 35.46% and a internet margin of 19.14%. The enterprise’s income for the quarter was up 5.2% in comparison with the identical quarter final yr. Throughout the identical quarter final yr, the corporate earned $2.66 earnings per share. On common, analysts forecast that Johnson & Johnson will publish 9.94 earnings per share for the present fiscal yr.
Johnson & Johnson Broadcasts Dividend
The agency additionally just lately declared a quarterly dividend, which can be paid on Tuesday, December tenth. Shareholders of document on Tuesday, November twenty sixth can be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized foundation and a yield of three.10%. The ex-dividend date of this dividend is Tuesday, November twenty sixth. Johnson & Johnson’s payout ratio is 71.78%.
Insiders Place Their Bets
In different Johnson & Johnson information, VP Robert J. Decker bought 5,635 shares of the agency’s inventory in a transaction dated Friday, August thirtieth. The inventory was bought at a mean worth of $165.06, for a complete worth of $930,113.10. Following the sale, the vp now immediately owns 18,973 shares of the corporate’s inventory, valued at roughly $3,131,683.38. This commerce represents a 0.00 % lower of their place. The sale was disclosed in a submitting with the Securities & Change Fee, which is accessible via this hyperlink. 0.16% of the inventory is owned by company insiders.
Johnson & Johnson Firm Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare subject worldwide. The corporate’s Modern Medication phase provides merchandise for numerous therapeutic areas, equivalent to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, equivalent to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension via retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Featured Tales
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Rankings for Johnson & Johnson Each day – Enter your e-mail deal with beneath to obtain a concise each day abstract of the newest information and analysts’ scores for Johnson & Johnson and associated firms with MarketBeat.com’s FREE each day e-mail e-newsletter.
